Peptide-coated polyurethane material reduces wound infection and inflammation

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Peptide-coated polyurethane material reduces wound infection and inflammation. / Stromdahl, Ann-Charlotte; Ignatowicz, Lech; Petruk, Ganna; Butrym, Marta; Wasserstrom, Sebastian; Schmidtchen, Artur; Puthia, Manoj.

In: Acta Biomaterialia, Vol. 128, 2021, p. 314-331.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Stromdahl, A-C, Ignatowicz, L, Petruk, G, Butrym, M, Wasserstrom, S, Schmidtchen, A & Puthia, M 2021, 'Peptide-coated polyurethane material reduces wound infection and inflammation', Acta Biomaterialia, vol. 128, pp. 314-331. https://doi.org/10.1016/j.actbio.2021.04.045

APA

Stromdahl, A-C., Ignatowicz, L., Petruk, G., Butrym, M., Wasserstrom, S., Schmidtchen, A., & Puthia, M. (2021). Peptide-coated polyurethane material reduces wound infection and inflammation. Acta Biomaterialia, 128, 314-331. https://doi.org/10.1016/j.actbio.2021.04.045

Vancouver

Stromdahl A-C, Ignatowicz L, Petruk G, Butrym M, Wasserstrom S, Schmidtchen A et al. Peptide-coated polyurethane material reduces wound infection and inflammation. Acta Biomaterialia. 2021;128:314-331. https://doi.org/10.1016/j.actbio.2021.04.045

Author

Stromdahl, Ann-Charlotte ; Ignatowicz, Lech ; Petruk, Ganna ; Butrym, Marta ; Wasserstrom, Sebastian ; Schmidtchen, Artur ; Puthia, Manoj. / Peptide-coated polyurethane material reduces wound infection and inflammation. In: Acta Biomaterialia. 2021 ; Vol. 128. pp. 314-331.

Bibtex

@article{5ea9d9b1862f47fb9965560e392e3f9c,
title = "Peptide-coated polyurethane material reduces wound infection and inflammation",
abstract = "There is an urgent need for treatments that not only reduce bacterial infection that occurs during wounding but that also target the accompanying excessive inflammatory response. TCP-25, a thrombin-derived antibacterial peptide, scavenges toll-like receptor agonists such as endotoxins and lipoteichoic acid and prevents toll-like receptor-4 dimerization to reduce infection-related inflammation in vivo. Using a combination of biophysical, cellular, and microbiological assays followed by experimental studies in mouse and pig models, we show that TCP-25, when delivered from a polyurethane (PU) material, exerts anti-infective and anti-inflammatory effects in vitro and in vivo. Specifically, TCP-25 killed the common wound pathogens, Pseudomonas aeruginosa and Staphylococcus aureus, in both in vitro and in vivo assays. Furthermore, after its release from the PU material, the peptide retained its capacity to induce its helical conformation upon endotoxin interaction, yielding reduced activation of NF-kappa B in THP-1 reporter cells, and diminished accumulation of inflammatory cells and subsequent release of IL-6 and TNF-alpha in subcutaneous implant models in vivo. Moreover, in a porcine partial thickness wound infection model, TCP-25 treated infection with S. aureus, and reduced the concomitant inflammatory response. Taken together, these findings demonstrate a combined antibacterial and anti-inflammatory effect of TCP-25 delivered from PU in vitro, and in mouse and porcine in vivo models of localized infection-inflammation.Statement of significanceLocal wound infections may result in systemic complications and can be difficult to treat due to increasing antimicrobial resistance. Surgical site infections and biomaterial-related infections present a major challenge for hospitals. In recent years, various antimicrobial coatings have been developed for infection prevention and current concepts focus on various matrices with added anti-infective components, including various antibiotics and antiseptics. We have developed a dual action wound dressing concept where the host defense peptide TCP-25, when delivered from a PU material, targets both bacterial infection and the accompanying inflammation. TCP-25 PU showed efficacy in in vitro and experimental wound models in mouse and minipigs. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc.",
keywords = "Wound, Host defense peptide, Lipopolysaccharide, Inflammation, Infection, HOST-DEFENSE PEPTIDES, ANTIMICROBIAL PEPTIDES, ENDOTOXIN, THROMBIN, RESPONSES, MODEL, CORTICOSTEROIDS, CYTOTOXICITY, RECRUITMENT, PERFORMANCE",
author = "Ann-Charlotte Stromdahl and Lech Ignatowicz and Ganna Petruk and Marta Butrym and Sebastian Wasserstrom and Artur Schmidtchen and Manoj Puthia",
year = "2021",
doi = "10.1016/j.actbio.2021.04.045",
language = "English",
volume = "128",
pages = "314--331",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Peptide-coated polyurethane material reduces wound infection and inflammation

AU - Stromdahl, Ann-Charlotte

AU - Ignatowicz, Lech

AU - Petruk, Ganna

AU - Butrym, Marta

AU - Wasserstrom, Sebastian

AU - Schmidtchen, Artur

AU - Puthia, Manoj

PY - 2021

Y1 - 2021

N2 - There is an urgent need for treatments that not only reduce bacterial infection that occurs during wounding but that also target the accompanying excessive inflammatory response. TCP-25, a thrombin-derived antibacterial peptide, scavenges toll-like receptor agonists such as endotoxins and lipoteichoic acid and prevents toll-like receptor-4 dimerization to reduce infection-related inflammation in vivo. Using a combination of biophysical, cellular, and microbiological assays followed by experimental studies in mouse and pig models, we show that TCP-25, when delivered from a polyurethane (PU) material, exerts anti-infective and anti-inflammatory effects in vitro and in vivo. Specifically, TCP-25 killed the common wound pathogens, Pseudomonas aeruginosa and Staphylococcus aureus, in both in vitro and in vivo assays. Furthermore, after its release from the PU material, the peptide retained its capacity to induce its helical conformation upon endotoxin interaction, yielding reduced activation of NF-kappa B in THP-1 reporter cells, and diminished accumulation of inflammatory cells and subsequent release of IL-6 and TNF-alpha in subcutaneous implant models in vivo. Moreover, in a porcine partial thickness wound infection model, TCP-25 treated infection with S. aureus, and reduced the concomitant inflammatory response. Taken together, these findings demonstrate a combined antibacterial and anti-inflammatory effect of TCP-25 delivered from PU in vitro, and in mouse and porcine in vivo models of localized infection-inflammation.Statement of significanceLocal wound infections may result in systemic complications and can be difficult to treat due to increasing antimicrobial resistance. Surgical site infections and biomaterial-related infections present a major challenge for hospitals. In recent years, various antimicrobial coatings have been developed for infection prevention and current concepts focus on various matrices with added anti-infective components, including various antibiotics and antiseptics. We have developed a dual action wound dressing concept where the host defense peptide TCP-25, when delivered from a PU material, targets both bacterial infection and the accompanying inflammation. TCP-25 PU showed efficacy in in vitro and experimental wound models in mouse and minipigs. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc.

AB - There is an urgent need for treatments that not only reduce bacterial infection that occurs during wounding but that also target the accompanying excessive inflammatory response. TCP-25, a thrombin-derived antibacterial peptide, scavenges toll-like receptor agonists such as endotoxins and lipoteichoic acid and prevents toll-like receptor-4 dimerization to reduce infection-related inflammation in vivo. Using a combination of biophysical, cellular, and microbiological assays followed by experimental studies in mouse and pig models, we show that TCP-25, when delivered from a polyurethane (PU) material, exerts anti-infective and anti-inflammatory effects in vitro and in vivo. Specifically, TCP-25 killed the common wound pathogens, Pseudomonas aeruginosa and Staphylococcus aureus, in both in vitro and in vivo assays. Furthermore, after its release from the PU material, the peptide retained its capacity to induce its helical conformation upon endotoxin interaction, yielding reduced activation of NF-kappa B in THP-1 reporter cells, and diminished accumulation of inflammatory cells and subsequent release of IL-6 and TNF-alpha in subcutaneous implant models in vivo. Moreover, in a porcine partial thickness wound infection model, TCP-25 treated infection with S. aureus, and reduced the concomitant inflammatory response. Taken together, these findings demonstrate a combined antibacterial and anti-inflammatory effect of TCP-25 delivered from PU in vitro, and in mouse and porcine in vivo models of localized infection-inflammation.Statement of significanceLocal wound infections may result in systemic complications and can be difficult to treat due to increasing antimicrobial resistance. Surgical site infections and biomaterial-related infections present a major challenge for hospitals. In recent years, various antimicrobial coatings have been developed for infection prevention and current concepts focus on various matrices with added anti-infective components, including various antibiotics and antiseptics. We have developed a dual action wound dressing concept where the host defense peptide TCP-25, when delivered from a PU material, targets both bacterial infection and the accompanying inflammation. TCP-25 PU showed efficacy in in vitro and experimental wound models in mouse and minipigs. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc.

KW - Wound

KW - Host defense peptide

KW - Lipopolysaccharide

KW - Inflammation

KW - Infection

KW - HOST-DEFENSE PEPTIDES

KW - ANTIMICROBIAL PEPTIDES

KW - ENDOTOXIN

KW - THROMBIN

KW - RESPONSES

KW - MODEL

KW - CORTICOSTEROIDS

KW - CYTOTOXICITY

KW - RECRUITMENT

KW - PERFORMANCE

U2 - 10.1016/j.actbio.2021.04.045

DO - 10.1016/j.actbio.2021.04.045

M3 - Journal article

C2 - 33951491

VL - 128

SP - 314

EP - 331

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

ER -

ID: 274525294